These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38883372)

  • 1. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
    Xie B; Gao Q; Wang Y; Du J; He Y
    Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.
    Januzzi JL; Prescott MF; Butler J; Felker GM; Maisel AS; McCague K; Camacho A; Piña IL; Rocha RA; Shah AM; Williamson KM; Solomon SD;
    JAMA; 2019 Sep; 322(11):1085-1095. PubMed ID: 31475295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
    Ge T; Yang Y; Zhao Y
    Perfusion; 2023 Nov; 38(8):1697-1704. PubMed ID: 36173344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
    JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Application of Sacubitril Valsartan Sodium After Acute Myocardial Infarction and its Influence on Ventricular Remodeling and TGF-β1/Smad3 Signaling Pathway.
    Wang L; Zhang Y; Xue J; Da Y; Gao Y; Sun Y; Zhou S
    Altern Ther Health Med; 2024 Aug; 30(8):98-103. PubMed ID: 38290462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment.
    Gu W; Xu C; Li Z; Li ZZ
    Cardiovasc Diagn Ther; 2021 Oct; 11(5):1093-1100. PubMed ID: 34815959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
    JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
    Chen C; Wu X; Li Y; Peng Y
    Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
    Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
    Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin combined with sacubitril/valsartan in hypertensive patients with heart failure: a retrospective study of efficacy and effect on blood pressure variability and cardiac function.
    Ma Y; Li W; Liu Y; Li L
    Am J Transl Res; 2024; 16(7):3036-3045. PubMed ID: 39114702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
    Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study.
    Zheng J; Wu Q; Li Q; Tang M; He J; Qiu Z; Xie L; Chen L
    J Cardiothorac Surg; 2023 Apr; 18(1):138. PubMed ID: 37041595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.